Safety and efficacy of botulinum toxin type A made in China for treatment of post-stroke upper limb spasticity: a randomized double-blind controlled trial
Yingmai Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Weifeng Luo, Rong-hua Tang, jianan li, Xudong Pan, Shengyuan Yu(Nankai University), Jiahong Lu(University of Macau), Zhiyu Nie, Enxiang Tao(Sun Yat-sen University), Huifang Shang(Sichuan University), Suling Chen(Key Laboratory of Guangdong Province), Lin Wang(Heilongjiang University), Jun Chen(Jilin University), Qiang Wu(Macau University of Science and Technology), Baorong Zhang(Jilin University), H. Tan, Hongjuan Dong(Xijing Hospital), Xueping Zhang, Xingyue Hu, Xinhua Wan, Qi Liang
Cited by 1
Related Papers
Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia
|Stroke|2012|1.6k
<i>In Vivo</i>Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis
|Journal of Neuroscience|2002|419
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
|Nature Biotechnology|2009|378
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity
|ACS Medicinal Chemistry Letters|2014|331